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Autologous and allogeneic progenitor cells (HPCs) can be
collected from bone marrow or from peripheral blood after
mobilization by growth factors, chemokines, and/or chemo-
therapy. HPCs are typically stored in autologous (donor)
plasma or macromolecules with a ﬁnal concentration of 5%
to 10% demethylsulfoxide within specially designed freezers
that use either gaseous or liquid nitrogen as the refrigerant.
Optimization of the complex process of stem cell processing
and storage has enabled successful stem cell transplantation
with cryopreserved CD34þ cells beyond 10 years of storage
[1-3]. However, for HPCs that have been stored for more than
a few years, the viability of the cellsdand therefore their
suitability for use in transplantdis unknown. In addition,
both regulatory and accrediting organizations require HPCs
to be labeled with expiration dates [4,5], leading to potential
confusion as to when and how to discard cryopreserved
HPCs. Other complicating factors include individual hospital
risk managementmedical-legal oversight and the inability to
identify transplant patients lost to follow-up.
Although clearly delineated consent forms that indicate
maximum storage time before discard have been developed,
some institutions view HPCs as “property” of patients and
therefore require documentation of death or consent before
discard. This process can be a clinical challenge unless the
patient’s death records can be obtained through the US Social
Security Death Master File [6]. Furthermore, there are no
currently available laboratory billing codes that enable stemhttp://dx.doi.org/10.1016/j.bbmt.2015.07.024
1083-8791/ 2015 American Society for Blood and Marrow Transplantation.cell processing laboratories to issue a bill for extended HPC
storage.
Despite these limitations, wewould advise careful review
of the cryopreserved inventory to determine if a stored
product could feasibly be used in patients who may be un-
suitable for transplant because of disease progression,
advanced age, or other reasons. After inventory assessment,
frozen HPCs for patients over age 75 or with other contra-
indications for stem cell transplantation may be discarded to
avoid costly consumption of hospital resources, which would
otherwise continue in perpetuity. Future data inquiries,
particularly surveys of transplant centers or stem cell labo-
ratories, may provide additional insight as to the extent of
extended storage, cryopreserved HPCs for transplantation
that are discarded and their associated direct and indirect
costs.
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